LifeTech Scientific Corporation has announced the publication of two-year follow-up results from its Phase II and Phase III clinical studies of the IBS® Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System. According to the announcement, the follow-up data from these clinical studies have been submitted to the National Medical Products Administration (NMPA) and to the European Union for CE registration approval. The company states that these results further enhance the evidence base for the IBS® Coronary Scaffold and are expected to support its global development. The results have already been presented and submitted to relevant regulatory authorities.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeTech Scientific Corporation published the original content used to generate this news brief on October 29, 2025, and is solely responsible for the information contained therein.